Printer Friendly

Allotex Completes Financing for Presbyopia Clinical Trials.

M2 PHARMA-March 5, 2018-Allotex Completes Financing for Presbyopia Clinical Trials

(C)2018 M2 COMMUNICATIONS

- Boston, Massachusetts-based presbyopia treatment developer Allotex has closed on financing from a strategic investor to fund its upcoming European clinical trials of its TransForm Corneal Allograft (TCA), the company said.

The TCA is created using natural human corneal tissue which has been shaped using high precision patented and proprietary technology.

These shaped lenticules can be placed in or on a patient's natural cornea with the aim of reducing or eliminating the need for wearing reading glasses.

The TCA has no biocompatibility issues because the natural collagen does not induce any immune response reactions. The safety of this approach has been established by over 50 years of corneal research and the company believes that the recent advances in lasers and metrology will allow the creation of precision implants and the predictable correction of presbyopia.

Co-founder Dr. Muller said "This funding will allow us to complete a multi-center clinical study to demonstrate the safety and effectiveness of the TCA.

The study will commence later this year and take place at prestigious ophthalmic centers in the UK, Ireland, Belgium, Austria, Switzerland and France."

Privately held Allotex is developing the TCA for the treatment of presbyopia. The company has developed processes and capabilities that it to make precisely shaped, natural implants.

It has a research facility in Zurich, Switzerland with production and corporate offices in Boston, Massachusetts.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Geographic Code:1U1MA
Date:Mar 5, 2018
Words:248
Previous Article:Concert Pharmaceuticals Selects CTP-692 for Development as Adjunctive Treatment of Schizophrenia.
Next Article:Aimmune Therapeutics Nets USD 164m in Public Offering of Common Stock.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters